Tocilizumab for the Treatment of Familial Mediterranean Fever—A Randomized, Double-Blind, Placebo-Controlled Phase II Study

Tocilizumab for the Treatment of Familial Mediterranean Fever—A Randomized, Double-Blind, Placebo-Controlled Phase II Study

Background: The purpose of this trial was to evaluate the effectiveness and safety of the IL-6 receptor antibody Tocilizumab (TCZ) in the treatment of Familial Mediterranean Fever (FMF). Methods: This was a randomized, double-blinded, placebo-controlled phase II trial in adult patients with active F...

Full description

Bibliographic Details
Main Authors: Joerg C. Henes, Sebastian Saur, David M. Kofler, Claudia Kedor, Christoph Meisner, Marion Schuett, Martin Krusche, Ina Koetter, Theodoros Xenitidis, Hendrik Schulze-Koops, Eugen Feist
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Journal of Clinical Medicine
Subjects:
Familial Mediterranean Fever
tocilizumab
interleukin 6
colchicine resistant
treatment
Online Access:https://www.mdpi.com/2077-0383/11/18/5360

Internet

https://www.mdpi.com/2077-0383/11/18/5360

Similar Items